Abbott Laboratories (NYSE:ABT) Issues Earnings Results, Beats Expectations By $0.02 EPS

Abbott Laboratories (NYSE:ABT - Get Free Report) released its quarterly earnings results on Wednesday. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02, Zacks reports. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. Abbott Laboratories updated its Q2 2025 guidance to 1.230-1.270 EPS and its FY 2025 guidance to 5.050-5.250 EPS.

Abbott Laboratories Stock Performance

NYSE ABT traded down $1.80 on Monday, hitting $129.18. 1,758,612 shares of the company's stock were exchanged, compared to its average volume of 6,010,206. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The firm's 50-day moving average price is $130.62 and its two-hundred day moving average price is $121.96. The firm has a market cap of $224.04 billion, a price-to-earnings ratio of 16.89, a P/E/G ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $141.23.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 annualized dividend and a yield of 1.83%. Abbott Laboratories's dividend payout ratio is currently 30.61%.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of recent research reports. Evercore ISI lifted their price target on shares of Abbott Laboratories to $136.00 and gave the stock a "buy" rating in a research note on Thursday, January 2nd. Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price target (up from $133.00) on shares of Abbott Laboratories in a report on Thursday. Stifel Nicolaus boosted their target price on Abbott Laboratories from $135.00 to $145.00 and gave the stock a "buy" rating in a research note on Thursday. Bank of America increased their target price on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Finally, Citigroup boosted their target price on Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $142.59.

Insider Activity at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the sale, the executive vice president now owns 125,697 shares of the company's stock, valued at approximately $16,152,064.50. The trade was a 15.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the completion of the transaction, the executive vice president now directly owns 71,928 shares of the company's stock, valued at approximately $9,625,404.96. This trade represents a 55.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 116,449 shares of company stock worth $15,463,316 over the last three months. 0.46% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Abbott Laboratories

An institutional investor recently raised its position in Abbott Laboratories stock. Brighton Jones LLC increased its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,719 shares of the healthcare product maker's stock after purchasing an additional 4,755 shares during the period. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 as of its most recent SEC filing. Institutional investors own 75.18% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.